

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

***APPLICATION NUMBER:***

**75288**

**APPROVAL LETTER**

JUL 28 1999

SCS Pharmaceuticals  
Attn: Doranne Frano  
4901 Searle Parkway  
Skokie, IL 60077

Dear Madam:

This is in reference to your abbreviated new drug application dated December 24, 1997, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act, for Low-Ogestrel-21 and Low-Ogestrel-28 (Norgestrel and Ethinyl Estradiol Tablets USP, 0.3 mg/0.03 mg, respectively, (21 and 28-day cycle packages).

Reference is also made to your amendments dated May 18, September 3, and October 16, 1998; and May 27, June 10, July 9, and July 15, 1999.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved. The Division of Bioequivalence has determined your Low-Ogestrel-21 and Low-Ogestrel-28 (Norgestrel and Ethinyl Estradiol Tablets USP, 0.3 mg/0.03 mg, respectively, to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Lo/Ovral Tablets and Lo/Ovral-28 Tablets, respectively, of Wyeth Ayerst Laboratories, Inc.). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under 21 CFR 314.70, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy, which you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-40). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FD-2253 at the time of their initial use.

Sincerely yours,

*R. L. Williams*

*/s/*

Roger L. Williams, M.D.  
Deputy Center Director for  
Pharmaceutical Science  
Center for Drug Evaluation and Research

*2/23/99*